Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Zymenex AS

Division of Chiesi Farmaceutici SPA
www.zymenex.com

Latest From Zymenex AS

Chiesi Takes Aim At Next-Generation Eosinophilic Asthma Therapy

Chiesi may be coming late to the development of eosinophilic asthma therapies, but there are certain advantages associated with acquisition target Atopix Therapeutics’ potential products that could strengthen the specialty pharma's already significant presence in the asthma market.

M & A Respiratory

European Notebook: EC Pharma Policy Reorganized; Early Access To Medicines Scheme Starts; U.K. Changing Merger Regs

Changes in responsibilities in new European Commission were welcomed by industry but not by health activists; and a brain cancer vaccine being developed by American biotech is selected to pioneer new early access scheme for innovative drugs being set up in the U.K.

BioPharmaceutical Europe

Deals Of The Week Watches An Unlikely HCIT Partnership: GSK & Community Care of North Carolina

GSK and CCNC, a non-profit network of health care providers, are developing a medication management analytics system that could get them into the health care IT business. For GSK, the main goal is to learn about changing dynamics of health care delivery systems, in a venture that is entirely independent of the company’s core drug business.

BioPharmaceutical United States

Deals Of The Week: How Do 2013 Biotech Deal Stats Stack Up After Amgen/Onyx?

A busy summer of biotech acquisitions, including the pricey buyouts of Onyx by Amgen and Elan by Perrigo, has lifted the number of U.S. public biotech acquisitions so far in 2013 – and increased the average value of those deals. In other deal news, Endo plans to acquire Boca Pharmacal, Medimmune will buy out Amplimmune, and Eli Lilly signed a diabetes research deal with Zealand Pharma.

BioPharmaceutical Deals
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Therapeutic Areas
  • Metabolic Disorders
  • Neurology, Nervous System
  • Alias(es)
  • HemeBiotech AS
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • Scandinavia
          • Denmark
  • Parent & Subsidiaries
  • Chiesi Farmaceutici SPA
  • Senior Management
  • Jens Fogh, Pres. & CEO
    Claes Andersson, PhD, Rsch. Dir.
  • Contact Info
  • Zymenex AS
    Phone: (45) 48250054
    Roskildevej 12C
    Hillerod, 3400
    Denmark
UsernamePublicRestriction

Register